PCCOX Performance — T. Rowe Price U.S. Equity Research Fund, I Class
Data updated: 2026-08-27
PCCOX returned +11.05% year to date and +22.60% over one year to Jun 2026. Annualised returns are +21.37% over 3 years and +14.04% over 5 years. The fund beat its US Large Blend category average: $100 invested three years ago grew to $179, against $157 for the category, and to $123 over one year, against $118. Volatility over the past three years was 13.29% a year. In the 12 months to Jun 2026 the fund took in a net $513.8M, and assets reached $18.52B.
PCCOX Growth of $100
What $100 invested in T. Rowe Price U.S. Equity Research Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Blend category average over the same months.
| Period | PCCOX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $123 | $118 |
| 3 years (Jul 2023 – Jun 2026) | $179 | $157 |
| 5 years (Jul 2021 – Jun 2026) | $193 | $161 |
| Since data start (Jul 2019 – Jun 2026) | $294 | $229 |
PCCOX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +11.05% |
| 1 year | +22.60% |
| 3 years (annualised) | +21.37% |
| 5 years (annualised) | +14.04% |
PCCOX Annual Returns
Calendar-year total returns of T. Rowe Price U.S. Equity Research Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +11.05% |
| 2025 | +16.49% |
| 2024 | +26.56% |
| 2023 | +29.89% |
| 2022 | −18.71% |
| 2021 | +28.07% |
| 2020 | +19.93% |
| 2019 (Jul–Dec) | +10.90% |
PCCOX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.6% | −0.6% | −5.4% | +11.0% | +5.2% | −0.5% | — | — | — | — | — | — |
| 2025 | +2.8% | −1.6% | −5.9% | −0.5% | +6.2% | +4.9% | +2.2% | +1.7% | +3.4% | +2.5% | +0.1% | +0.1% |
| 2024 | +2.3% | +5.8% | +3.1% | −3.9% | +5.2% | +3.8% | +0.6% | +2.4% | +2.0% | −0.8% | +5.9% | −2.1% |
| 2023 | +6.7% | −2.3% | +3.8% | +2.2% | +1.1% | +6.4% | +3.4% | −1.3% | −4.6% | −2.0% | +9.4% | +4.6% |
| 2022 | −5.0% | −2.9% | +3.2% | −9.2% | −0.1% | −7.9% | +9.6% | −4.2% | −9.1% | +7.7% | +5.5% | −5.8% |
| 2021 | −1.7% | +2.9% | +4.3% | +5.8% | +0.7% | +2.2% | +2.4% | +3.0% | −4.4% | +6.8% | −0.9% | +4.6% |
| 2020 | +0.1% | −7.9% | −13.0% | +12.6% | +5.0% | +2.0% | +6.2% | +7.3% | −4.1% | −2.4% | +11.7% | +4.1% |
| 2019 | — | — | — | — | — | — | +1.4% | −1.6% | +1.7% | +2.3% | +3.8% | +2.9% |
PCCOX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 13.29%
- 3-year Sharpe ratio: 1.27 (vs 4.5% risk-free rate)
- Best month: +11.04% (Apr 2026)
- Worst month: −5.91% (Mar 2025)
PCCOX Fund Flows
Monthly money in and out of T. Rowe Price U.S. Equity Research Fund, from SEC Form N-PORT.
- 12-month net flow: $513.8M
- 12-month gross sales (incl. reinvestments): $4.8B
- Sales ÷ redemptions: 1.12×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $342.4M | $461.3M | −$118.9M |
| May 2026 | $491.9M | $331.1M | $160.8M |
| Apr 2026 | $550.0M | $264.5M | $285.5M |
| Mar 2026 | $430.6M | $528.3M | −$97.7M |
| Feb 2026 | $282.9M | $243.0M | $39.9M |
| Jan 2026 | $421.2M | $275.4M | $145.9M |
| Dec 2025 | $499.5M | $449.0M | $50.5M |
| Nov 2025 | $305.5M | $321.2M | −$15.7M |
| Oct 2025 | $300.5M | $261.9M | $38.6M |
| Sep 2025 | $518.2M | $354.4M | $163.8M |
| Aug 2025 | $261.9M | $400.6M | −$138.6M |
| Jul 2025 | $391.8M | $392.0M | −$196K |
PCCOX Assets Under Management
Net assets of T. Rowe Price U.S. Equity Research Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $18.52B |
| 2026-03-31 | $15.64B |
| 2025-12-31 | $16.27B |
| 2025-09-30 | $15.97B |
| 2025-06-30 | $14.83B |
| 2025-03-31 | $13.07B |
| 2024-12-31 | $13.58B |
| 2024-09-30 | $12.51B |
| 2024-06-30 | $11.64B |
| 2024-03-31 | $11.34B |
| 2023-12-31 | $10.70B |
| 2023-09-30 | $10.20B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.